Ser211

Site Information
ESKLLsAsQLsAEEE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 481755
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	luminal A breast cancer ( 1 ) , lung cancer ( 2 , 3 , 4 ) , non-small cell lung cancer ( 4 ) , small-cell lung cancer ( 2 , 3 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , DMS53 (pulmonary) ( 3 ) , DMS79 (pulmonary) ( 2 ) , H2077 (pulmonary) ( 4 ) , H322M (pulmonary) ( 4 ) , HEK293T (epithelial) ( 5 ) , lung ( 2 , 3 ) , NCI-H128 (pulmonary) ( 2 ) , NCI-H1417 (pulmonary) ( 2 ) , NCI-H209 (pulmonary) ( 2 ) , NCI-H446 (pulmonary) ( 3 ) , NCI-H524 (pulmonary) ( 2 ) , NCI-H526 (pulmonary) ( 3 ) , NCI-H69 (pulmonary) ( 3 ) , NCI-H82 (pulmonary) ( 3 )

Upstream Regulation
Treatments:	ionizing_radiation ( 5 ) , UV ( 5 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
5	Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6 17525332 Curated Info